Genus PLC banner

Genus PLC
LSE:GNS

Watchlist Manager
Genus PLC Logo
Genus PLC
LSE:GNS
Watchlist
Price: 2 568 GBX -0.77% Market Closed
Market Cap: £1.7B

Genus PLC
Total Equity

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Genus PLC
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Genus PLC
LSE:GNS
Total Equity
£504m
CAGR 3-Years
-4%
CAGR 5-Years
0%
CAGR 10-Years
5%
Bicycle Therapeutics PLC
NASDAQ:BCYC
Total Equity
$610m
CAGR 3-Years
31%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Total Equity
£381m
CAGR 3-Years
11%
CAGR 5-Years
47%
CAGR 10-Years
N/A
Compass Pathways PLC
NASDAQ:CMPS
Total Equity
-$52.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Oxford BioMedica PLC
LSE:OXB
Total Equity
£91.3m
CAGR 3-Years
-24%
CAGR 5-Years
-4%
CAGR 10-Years
24%
Niox Group PLC
LSE:NIOX
Total Equity
£73.7m
CAGR 3-Years
-3%
CAGR 5-Years
0%
CAGR 10-Years
-16%
No Stocks Found

Genus PLC
Glance View

Market Cap
1.7B GBX
Industry
Biotechnology

Amidst the rolling countryside of Britain, Genus PLC has quietly but profoundly reshaped the agricultural landscape since its formation. With roots tracing back to the British government's Milk Marketing Board, Genus blossomed into an influential player at the intersection of biotechnology and farming. This was not by chance, but through a strategic evolution into a global pioneer in animal genetics. At the heart of their operations, Genus enhances animal breeding by leveraging cutting-edge science, particularly the technology of selective breeding and genetics. They focus primarily on two types of livestock: bovine (cattle) and porcine (pigs), catering to agricultural sectors worldwide. Essentially, through their subsidiaries—ABS Global, focusing on cattle, and PIC, specializing in pigs—the company maximizes genetic improvements, aiding farmers in producing leaner, more disease-resistant, and ultimately more productive livestock. The business model of Genus PLC revolves around the intricate science of animal genetics and the commercial viability it crafts from this foundation. By developing genetically superior livestock, they provide a distinct competitive advantage to farmers who seek more yield with less resource input. The company harnesses sophisticated techniques like genomics and advanced biotechnologies, including gene editing, to achieve these outcomes. With each genetic line licensed, Genus receives a license fee, ensuring a steady stream of revenue. Additionally, sales channels are bolstered by continuous consultative partnerships with farmers to enhance productivity, cementing a cycle of value that perpetuates mutual growth. By marrying science with agricultural prosperity, Genus PLC remains a vanguard in a field where innovation is as essential as the soil itself.

GNS Intrinsic Value
1 797.21 GBX
Overvaluation 30%
Intrinsic Value
Price GBX2 568

See Also

What is Genus PLC's Total Equity?
Total Equity
504m GBP

Based on the financial report for Dec 31, 2025, Genus PLC's Total Equity amounts to 504m GBP.

What is Genus PLC's Total Equity growth rate?
Total Equity CAGR 10Y
5%

Over the last year, the Total Equity growth was 4%. The average annual Total Equity growth rates for Genus PLC have been -4% over the past three years , and 5% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett